SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Torrent Pharmaceuticals informs about clarification

14 Aug 2024 Evaluate
With reference to e-mail received from BSE on 13th August, 2024 and the letter received from NSE, bearing reference no. NSE/CM/Surveillance/14603 dated 13th August, 2024, seeking clarification/ confirmation in respect of the news item appeared on the ‘Websitewww.economictimes.com’ captioned – ‘Torrent Pharma is said to seek raising $3 billion for KKR s stake in JB Chemicals’ on 13th August, 2024, Torrent Pharmaceuticals has clarified as follows: In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ‘Listing Regulations’), the Company has promptly intimated the stock exchanges regarding all events and disclosed all information, that have a bearing on the operations / performance of the Company which include all price sensitive information, etc., as and when required; At this stage, there is no material event/ information that requires disclosure under Regulation 30 of the Listing Regulations. If and when any proposal warranting a disclosure is considered by the board of directors of the Company, the Company shall promptly comply with the disclosure obligations under Regulation 30 of the Listing Regulations; Considering that the shares of the Company are freely traded on the stock exchanges, they noted that there has been no material price movement, and accordingly, the Company does not have any further comments.

The above information is a part of company’s filings submitted to BSE. 

Torrent Pharma Share Price

4410.75 -108.50 (-2.40%)
12-May-2026 14:17 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1859.10
Dr. Reddys Lab 1276.25
Cipla 1303.10
Zydus Lifesciences 935.75
Lupin 2269.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×